Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elamipretide in stable heart failure with preserved ejection fraction
2015-005615-32Phase 2Completed
- Sponsor
- Stealth BioTherapeutics
- Start
- Feb 2016
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in heart failure with preserved ejection fraction (HFpEF) comparing Elamipretide with Placebo (2 arms). Primary endpoint: Change in E/e' at rest. Started Feb 2016; status: completed.
02
Drugs
elamipretide
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on 2015-005615-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005615-32.